Dynavax Technologies has appointed Dr Robert Janssen as Chief Medical Officer and Vice President, Clinical Development. Janssen most recently served as Dynavax's Vice President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 to 2012, during which time he was extensively involved with Phase 3 clinical development of HEPLISAV and its US and European licensing applications.
Prior to joining Dynavax, Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies.
Until 2008, he spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV.
‘Rob has proven an invaluable member of the management team and we look forward to his ongoing contributions to the organisation,’ said Eddie Gray, Dynavax's Chief Executive Officer.
